logo

Sunesis Pharmaceuticals Inc. (SNSS)



Trade SNSS now with
  Date
  Headline
6/23/2020 7:39:50 AM Sunesis Not To Advance Vecabrutinib To Phase 2 Portion Of Phase 1b/2 Trial
9/19/2019 7:14:07 AM Sunesis Names Nicole Onetto To Board
9/19/2019 7:06:44 AM Sunesis Pharma Appoints Nicole Onetto To Board Of Directors
7/11/2019 12:33:45 AM Sunesis Pharmaceuticals Reports Pricing Of $25 Mln Offering Of Securities
6/15/2019 12:47:55 PM Sunesis Pharma Presents Preliminary Data From Phase 1b/2 Trial Of Vecabrutinib At EHA Annual Meeting
3/7/2019 4:10:05 PM Sunesis Pharmaceuticals Q4 Loss/share $0.16 Vs. Loss $0.21 Year Ago
1/2/2019 7:08:49 AM Sunesis Reports Advancement Into 100mg Cohort Of Phase 1b/2 Trial Of Vecabrutinib
7/30/2013 9:39:01 AM RBC Capital Markets Is Raising Sunesis Pharmaceuticals Inc. (SNSS) FY13 Estimate To -0.85 From -0.90
7/30/2013 9:16:46 AM RBC Capital Markets Is Raising Sunesis Pharmaceuticals Inc. (SNSS) FY13 Rev. Estimate To 5.0 M From 3.5 M
7/30/2013 9:15:48 AM RBC Capital Markets Is Lowering Sunesis Pharmaceuticals Inc. (SNSS) 4Q13 Estimate To -0.23 From -0.20
7/30/2013 9:15:27 AM RBC Capital Markets Is Lowering Sunesis Pharmaceuticals Inc. (SNSS) 3Q13 Estimate To -0.23 From -0.22